EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of GNX80 in Patients with Peripheral Arterial Disease and Intermittent Claudication

Onyou Kim iD, Seung Hun Lee iD, Jang Yong Kim iD, Wonho Kim iD, Han Cheol Lee iD, Ji Woong Roh iD, Jin Hyeon Joh iD, Sang-Ho Park iD, Sanghoon Shin iD, Sung-Hun Park Md iD, Woohyeun Kim iD, Hyung Joon Ahn iD und 5 weitere

Korean Circulation Journal · 2027 · 57

DOI: 10.4070/kcj.2026.0176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Circulation Journal, 2027. Verfasst von Onyou Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SK chemicals Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Peripheral arterial disease (PAD) is associated with intermittent claudication (IC), leading to a lower quality of life. Although Ginkgo biloba extract (GbE) has been investigated for the treatment of IC, its clinical efficacy remains controversial. This study aimed to evaluate the efficacy and safety of high-dose, long-term GbE therapy in patients with PAD and IC. METHODS: This randomized, double-blind, placebo-controlled, multicenter phase 4 trial enrolled patients with stable PAD and Fontaine stage IIb IC from 15 hospitals in South Korea. Participants were randomly assigned at a ratio of 1:1 to receive 80 mg of GbE (GNX80) twice daily or a placebo twice daily for 24 weeks. The primary endpoint was changes in the maximal walking distance (MWD) assessed using standardized treadmill testing after 24 weeks. RESULTS: At 24 weeks, in the full analysis set (FAS), GNX80 treatment was associated with a numerically greater improvement in MWD than placebo that did not reach statistical significance (58.95±129.79 vs. 12.09±131.33 m; p=0.095); a significant difference was observed in the pre-specified per-protocol analysis (p=0.041). The overall incidence of adverse events was similar between the GbE and placebo groups, and no new safety signals or treatment-discontinuing adverse events were observed. CONCLUSIONS: For patients with stable PAD and IC, GNX80 was associated with a numerically greater improvement in MWD compared with placebo, although statistical significance was not achieved in the primary FAS analysis. Further randomized trials are warranted to determine whether GNX80 improves functional capacity in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05400395.

Schlagwörter

Stichwörter der Autor:innen

Ginkgo biloba extractIntermittent claudicationPeripheral arterial disease

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
  • Department of Medicine, Graduate School, Korea University, Seoul, Korea.
  • Department of Vascular and Transplant Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
  • Division of Cardiology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.
  • Division of Cardiology, Pusan National University Hospital, Busan, Korea.
  • Division of Cardiology, Department of Internal Medicine, Cardiovascular Center, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.

ORCID-Profile: Onyou Kim, Seung Hun Lee, Jang Yong Kim, Wonho Kim, Han Cheol Lee, Ji Woong Roh, Jin Hyeon Joh, Sang-Ho Park, Sanghoon Shin, Sung-Hun Park Md, Woohyeun Kim, Hyung Joon Ahn, Ho Kyun Lee, Sang Hoon Kim, Sung-Ho Her, Seung-Woon Rha, Cheol Woong Yu

Förderung

  • SK chemicals Co., Ltd.

Zitieren

APA

Kim, O., Lee, S. H., Kim, J. Y., Kim, W., Lee, H. C., Roh, J. W., Joh, J. H., Park, S. H., Shin, S., Md, S. P., Kim, W., Ahn, H. J., Lee, H. K., Kim, S. H., Her, S. H., Rha, S. W., & Yu, C. W. (2027). Efficacy and Safety of GNX80 in Patients with Peripheral Arterial Disease and Intermittent Claudication. Korean Circulation Journal, 57. https://doi.org/10.4070/kcj.2026.0176

Vancouver

Kim O, Lee SH, Kim JY, Kim W, Lee HC, Roh JW, et al. Efficacy and Safety of GNX80 in Patients with Peripheral Arterial Disease and Intermittent Claudication. Korean Circulation Journal. 2027;57. doi:10.4070/kcj.2026.0176

BibTeX
@article{Kim2027,
  author = {Kim, Onyou and Lee, Seung Hun and Kim, Jang Yong and Kim, Wonho and Lee, Han Cheol and Roh, Ji Woong and Joh, Jin Hyeon and Park, Sang-Ho and Shin, Sanghoon and Md, Sung-Hun Park and Kim, Woohyeun and Ahn, Hyung Joon and Lee, Ho Kyun and Kim, Sang Hoon and Her, Sung-Ho and Rha, Seung-Woon and Yu, Cheol Woong},
  title = {Efficacy and Safety of GNX80 in Patients with Peripheral Arterial Disease and Intermittent Claudication},
  journal = {Korean Circulation Journal},
  year = {2027},
  volume = {57},
  doi = {10.4070/kcj.2026.0176}
}
Kostenlos starten →